"Managing biosimilar drugs is a major challenge for insurers, said Marie-Hélène Dugal, Product Portfolio Manager, Drug Insurance Management Solutions for Medavie Blue Cross, during its annual seminar.

Learn more about the various approaches to consider to cover these drugs while ensuring plan sustainability. "It's all a matter of balancing access to care and the sustainability of plans."

Read the full article here (In French Only)